Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intralytix, a biotechnology company, has received a new patent from the US Patent and Trademark Office covering the use of bacteriophages to reduce the risk of bacterial infection in persons colonized with pathogenic bacteria including Methicillin-resistant Staphylococcus aureus.
Subscribe to our email newsletter
According to the company, the patent broadly relates to the administration of compositions containing bacteriophages to individuals colonized with pathogenic bacteria in order to prevent the development of bacterial infections. The claims cover the general method, means and routes of administration, and specific cases including Methicillin-resistant Staphylococcus aureus (MRSA).
The claimed methods covered by the patent are particularly important for preventing life-threatening bacterial infections, treating immunocompromised patients (including patients undergoing cancer chemotherapy), and reducing the incidence of antibiotic resistant infections. The patent covers the use of key Intralytix products, including a nasal bacteriophage spray to significantly reduce or eliminate colonization by Staphylococcus aureus, including MRSA.
John Vazzana, CEO of Intralytix, said: “Bacterial infections of immunocompromised and seriously ill patients, as well as antibiotic resistant infections are serious problems in today’s world. We are excited that our technology has been recognized as an innovative approach to help solve these problems. We look forward to bringing this technology to market.”